Select Publications

Banning M. Advanced breast cancer: Aetiology, treatment and psychosocial features. Br J Nurs 2007;16(2):86-90. Abstract

Berterö, Chamberlain Wilmoth M. Breast cancer diagnosis and its treatment affecting the self: A meta-synthesis. Cancer Nurs 2007;30(3):194-202. Abstract

Boehmke MM, Dickerson SS. The diagnosis of breast cancer: Transition from health to illness. Oncol Nurs Forum 2006;33(6):1121-7. Abstract

Byar KL et al. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum 2006;33(1):E18-26. Abstract

Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.  Oncol Nurs Forum 2006;33(2):265-72. Abstract

Clemens M et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: Results of a post-hoc analysis from the TAnDEM study. ASCO 2007 Breast Cancer Symposium;Abstract 231.

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract

Epstein DR, Dirksen, SR. Randomized trial of a cognitive-behavioral intervention for insomnia in breast cancer survivors. Oncol Nurs Forum 2007;34(5):E51-9. Abstract

Frankel C. Choosing the appropriate breast cancer therapy for today's breast cancer patient. Semin Oncol Nurs 2007;23(4 Suppl 2):3-9. Abstract

Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract

Goss PE. Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 2006;33(2 Suppl 7):8-12. Abstract

Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract

Gradishar w et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Proc ASCO 2007; Abstract 1032.

Heidrich SM et al. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: A comparative study. Oncol Nurs Forum 2006;33(2):315-22. Abstract

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract

Khan QJ et al. A prospective study to determine the prevalence of hypovitaminosis D in women with early stage breast cancer treated with an aromatase inhibitor and the benefit of vitamin D supplementation on musculoskeletal symptoms and overall QOL. Poster. San Antonio Breast Cancer Symposium 2007;Abstract 6075.

Keller JS. Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 2006;10(1):57-60. Abstract

Lester J. Breast cancer in 2007: Incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs 2007;11(5):619-22. Abstract

Meneses KD et al. Transition from treatment to survivorship: Effects of a psychoeducational intervention on quality of life in breast cancer survivors. Oncol Nurs Forum 2007;34(5):1007-16. Abstract

Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract

Moore S. Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs 2007;23(4 Suppl 2):23-30. Abstract

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Partridge AH et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26(4):556-62. Abstract

Partridge AH et al. Adherence with adjuvant anastrozole therapy among women with early stage breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 4044.

Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006;17(2):183-4. No abstract available.

Payne J et al. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: A pilot study. Oncol Nurs Forum 2006;33(4):775-83. Abstract

Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.

Perez EA et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Proc ASCO 2007;Abstract 512.

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sledge GW et al. Adjuvant trastuzumab: Long-term results of E2198. San Antonio Breast Cancer Symposium 2006;Abstract 2075.

Ulhoa-Cintra A et al. The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep 2008;10(1):10-7. Abstract

Vahdat L. Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13(3):214-21. Abstract

Wickham R. Chemotherapy-induced peripheral neuropathy: A review and implications for oncology nursing practice. Clin J Oncol Nurs 2007;11(3):361-76. Abstract

Winkeljohn DL. Oral chemotherapy medications: The need for a nurse's touch. Clin J Oncol Nurs 2007;11(6):793-6. Abstract

Winters L et al. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs 2007;11(3):433-9. Abstract

Table of Contents

Top of Page